JP2024527576A - 抗ｔｎｆｒ２抗体及びその使用 - Google Patents

抗ｔｎｆｒ２抗体及びその使用 Download PDF

Info

Publication number
JP2024527576A
JP2024527576A JP2024500409A JP2024500409A JP2024527576A JP 2024527576 A JP2024527576 A JP 2024527576A JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024527576 A JP2024527576 A JP 2024527576A
Authority
JP
Japan
Prior art keywords
seq
sequence
antigen
tnfr2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527576A5 (https=
Inventor
ベルトラミネリ，ニコラ・アルトゥーロ・アルド
ワトキンス，ジェニファー
エイドリアン，フランシスコ
チャン，チェン
ラウエ，アンドレアス
メアリー，パスカリーヌ
シュバイツァー，リャン
ウェイ，シュオ
デリンス，マテュー
Original Assignee
ハイファイバイオ（ホンコン）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハイファイバイオ（ホンコン）リミテッド filed Critical ハイファイバイオ（ホンコン）リミテッド
Publication of JP2024527576A publication Critical patent/JP2024527576A/ja
Publication of JP2024527576A5 publication Critical patent/JP2024527576A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024500409A 2021-07-07 2022-07-06 抗ｔｎｆｒ２抗体及びその使用 Pending JP2024527576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219175P 2021-07-07 2021-07-07
US63/219,175 2021-07-07
PCT/IB2022/000409 WO2023281313A1 (en) 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof

Publications (2)

Publication Number Publication Date
JP2024527576A true JP2024527576A (ja) 2024-07-25
JP2024527576A5 JP2024527576A5 (https=) 2025-07-18

Family

ID=84800439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500409A Pending JP2024527576A (ja) 2021-07-07 2022-07-06 抗ｔｎｆｒ２抗体及びその使用

Country Status (9)

Country Link
EP (1) EP4367140A4 (https=)
JP (1) JP2024527576A (https=)
KR (1) KR20240032985A (https=)
CN (1) CN117980336A (https=)
AR (1) AR126387A1 (https=)
AU (1) AU2022308421A1 (https=)
CA (1) CA3224693A1 (https=)
TW (1) TW202309096A (https=)
WO (1) WO2023281313A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3256751A1 (en) * 2022-05-26 2023-11-30 Pfizer Inc. Anti-TNFR2 antibodies and their methods of use
WO2024233258A1 (en) * 2023-05-05 2024-11-14 Cureimmune Therapeutics Inc. Anti-tnfr2 antibodies and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2021023098A1 (zh) * 2019-08-02 2021-02-11 江苏先声药业有限公司 抗tnfr2抗体及其用途
CN112480259A (zh) * 2021-02-05 2021-03-12 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途
WO2021055253A2 (en) * 2019-09-17 2021-03-25 Apexigen, Inc. Anti-tnfr2 antibodies and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190135929A1 (en) * 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3707163A4 (en) * 2017-11-09 2021-08-18 The General Hospital Corporation POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
CA3131953A1 (en) * 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2021023098A1 (zh) * 2019-08-02 2021-02-11 江苏先声药业有限公司 抗tnfr2抗体及其用途
WO2021055253A2 (en) * 2019-09-17 2021-03-25 Apexigen, Inc. Anti-tnfr2 antibodies and methods of use
CN112480259A (zh) * 2021-02-05 2021-03-12 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"'Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities inimmunosupp", CANCER RES., vol. Vol.80, 16_Supplement, JPN6026012432, 2020, pages 2282, ISSN: 0005826473 *

Also Published As

Publication number Publication date
AU2022308421A1 (en) 2024-01-25
CA3224693A1 (en) 2023-01-12
EP4367140A4 (en) 2025-06-18
AR126387A1 (es) 2023-10-11
WO2023281313A1 (en) 2023-01-12
TW202309096A (zh) 2023-03-01
EP4367140A1 (en) 2024-05-15
CN117980336A (zh) 2024-05-03
KR20240032985A (ko) 2024-03-12

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP6971850B2 (ja) がんの併用療法
US20230416382A1 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
JP7801225B2 (ja) 抗ｔｎｆｒ２抗体及びその使用
JP2024527576A (ja) 抗ｔｎｆｒ２抗体及びその使用
US12617860B2 (en) Anti-TNFR2 antibody and uses thereof
WO2021129744A1 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40092079A (zh) 抗tnfr2抗体和其用途

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260327